Apnimed

IPO

Breathing New Life Into OSA & More

Public · Cambridge, United States · Founded 2017 · $163.3M raised

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$163.3M
Last Round
$79.8M Series CJan 2023
Rounds
5
Type
Public

About

Apnimed is a clinical-stage biopharmaceutical company developing pharmacological treatments for obstructive sleep apnea (OSA). Founded in 2017 and headquartered in Cambridge, Massachusetts, the company's lead program AD109 is a combination of atomoxetine and oxybutynin targeting the pharyngeal muscles that cause airway collapse during sleep, offering a potential non-CPAP oral therapy for OSA.

Summary

Apnimed is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $163.3M in total across 5 rounds, most recently a $79.8M Series C round in Jan 2023. Investors include Healthcare Royalty Partners, Morningside Group and Shionogi.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJul 2026
$192.0M

Sign up to see all 7 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Apnimed on Indexed.vc
<a href="https://indexed.vc/companies/apnimed"><img src="https://indexed.vc/api/badge/company/apnimed" alt="Apnimed on Indexed.vc" width="260" height="76" /></a>